ABSTRACT
The HSV life cycle is complex, consisting of five stages: primary mucocutaneous infection, acute infection of nerve ganglia, establishment of life-long latency, reactivation, and recurrent infection (Figure 1) . 4 Exposure to HSV at mucosal surfaces or abraded skin permits entry of the virus into epidermal and dermal cells and the initiation of viral replication, s Following primary infection, which can be symptomatic or asymptomatic, the virus travels to the neuronal nuclei in the dorsal root ganglia, where it remains latent for indefinite periods. 4 The ability to persist in cells indefinitely, escaping elimination by the host's immune mechanisms, is one of the most perplexing aspects of the herpesviruses. 6 Patients with a first episode of genital herpes may have either a true primary infection or an initial genital HSV-2 infection (nonprimary first episode). Symptomatic true primary infections are typically severe and pregnancy may play a role. [4] [5] [6] When reactivation is triggered, the virus is released from infected dorsal root ganglia to reestablish active infection. 7 Recurrences are shorter and less intense than primary infections and are generally more severe in women than in men. 7 (Figure 2) . [15] [16] [17] Once penciclovir enters herpesvirusinfected cells, it is rapidly converted to its active metabolite, penciclovir triphosphate, which is, in part, dependent on the viral enzyme thymidine kinase, and stops subsequent replication of the virtls. ll '17-z0 The intracellular half-life of penciclovir triphosphate in vitro is 20 hours in HSV-2-infected cells (Table 1) . 11'16 Little unchanged famciclovir is found in the plasma, and the overall bioavailability of penciclovir from oral famciclovir is approximately 77% 14,2s
In the clinic-initiated study, the duration of viral shedding was reduced by more than 50% (1.6 days for 125-mg of famciclovir versus 3.4 days for placebo [P 0.0001]). Median time to complete healing was shorter for patients receiving 125-mg doses of famciclovir, compared with placebo-treated patients (P 0.0009). 28 In the patient-initiated study, the duration of viral shedding was reduced by almost two days with famciclovir treatment, from a median of 3.3 days with placebo to a median of 1.7 days with 125 mg of famciclovir. Of the patients who were viral-culture-negative prior to initiation of therapy, 73% of those treated with famciclovir remained culture-negative, compared with 46% of patients receiving placebo. 14 The median time to loss of all symptoms was 3.2 days for patients treated with 125 mg of famciclovir, compared with 3.7 days for placebo-treated patients (P < 0.01 based on a hazard ratio of 1.6).
14 Median time to complete healing was 3.8 days for patients receiving 125 mg of famciclovir, compared with 4.8 days for placebo-treated patients. 14 The efficacy of famciclovir has also been evaluated for the suppression of genital herpes. Women (n 375) with a history of six or more episodes of recurrent genital herpes per year were treated with famciclovir (125 mg, once or twice daily; 250 mg, once or twice daily; or 500 mg, once daily) or placebo for four months, z9 All doses of famciclovir were effective in suppressing HSV recurrences; however, famciclovir in doses of 250 mg, twice daily, was clearly the most effective, z9 In addition, the proportion of patients who remained free of HSV recurrences during the 120-day study increased from 48% in the placebo-treated group to 90% in patients receiving famciclovir in doses of 250 mg, twice daily (P < 0.001).z9
The meta-analysis of two year-long clinical trials, in which 369 patients were enrolled (236 receiving famciclovir, 250 mg, twice daily; 133 receiving placebo), showed that 80% fewer genital herpes outbreaks occurred in famciclovir-treated patients (median number of recurrences was 1) than in placebo-recipients (median number of recurrences was 4.9) (Data on file, SmithKline Beecham Pharmaceuticals). These and other studies show that once-daily dosing is less effective at preventing outbreaks than is multidosing, z9-31 The efficacy of famciclovir for the treatment of first-episode genital herpes was evaluated in three studies, which enrolled a total of 951 patients. In two of these studies, famciclovir, 250 mg, 500 mg, and 750 mg, three times for a day for five days, was compared with acyclovir, 200 mg, five times a day for five days; in the third study, famciclovir, 125 mg, 250 mg, and 500 mg, three times a day for 
